Exciting medical devices company founded by University of Melbourne scientists.
Company at forefront of developing a world-first, revolutionary rapid diagnostic devices using proprietary technology.
Products range from rapid Covid-19 test, to STD tests and cancer biomarker tests, with wide range of medical applications.
Company looking to partner with investors and/or industry professionals to launch its products in the US, EU, Asia and Australia.
Company already received two rounds of financing from professional investors and looking to invite new investors to participate in the 3rd round of financing.
Company's first human female-use, Chlamydia rapid test has been successfully developed, awaiting clinical trials and regulatory approval as soon as funding is in place. A related product, a Chlamydia rapid test for Koalas, is expected to reach the animal test market by mid-2024, followed by expansions into the much larger livestock rapid test market.
Suit high net worth, sophisticated investors including family offices, medical professionals interested in high-growth, high-tech exposure, with massive upside potential.
